A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

Summary

Patients suffering from histologically or cytologically confirmed stage IV lung or breast cancer with progressive or recurrent brain metastases after prior external beam radiotherapy will receive treatment with cabazitaxel until progression of brain metastases (BM) or unacceptable toxicity.

Timeline

Start

2015-08

Primary completion

2017-04

Completion

2018-01-18

Outcome

Outcome not reported

Stopped (Enrollment): “After a recruitment of more than 2 years, only 8 patients have been registered.”

Drugs

Indications